StocksMedium•3 November 2026•
1 min read
Bayer Raises Full-Year Guidance on Pharma Growth Amid Litigation Pressures
Key Facts
1Bayer raised its full-year guidance following growth in Q3 sales and EBITDA led by its pharmaceutical division.
2Impairments and legal-settlement payments weighed on the company's net income and free cash flow.
3The company's net debt declined despite financial pressures from legal issues.
Bayer raised its full-year guidance following growth in Q3 2026 sales and EBITDA. TradingView reported that the pharmaceutical division led the company's performance, prompting the upward revision of its annual financial targets.
Impairments and legal-settlement payments weighed on the company's net income and free cash flow, although net debt declined despite these financial pressures. BAYRY closed at $13.95 on November 2, 2026, having traded between a low of $13.86 and a high of $14.03 during that session.